Forbes August 1, 2023
Almost immediately following the regular approval by the Food and Drug Administration of the Alzheimer’s disease biologic Leqembi (lecanemab), the Centers for Medicare and Medicaid Services announced it will cover most patients eligible for the therapeutic. This includes patients with mild cognitive impairment or mild dementia with confirmed amyloid plaques.
Amyloid plaques are accumulations of beta amyloid proteins which clump together between the neurons in the brains of Alzheimer’s disease patients. Physicians confirm the existence of beta amyloid plaque in patients by performing brain scans.
CMS is requiring that Medicare beneficiaries who take Leqembi enroll in a patient registry to collect more data on the drug. The patient registry requirement is also a prerequisite for reimbursement of Leqembi.
In April...
Today's Sponsors
Today's Sponsor